People: OXiGENE Inc (OXGN.OQ)

OXGN.OQ on NASDAQ Stock Exchange Capital Market

2.89USD
2 Aug 2013
Price Change (% chg)

$0.08 (+2.85%)
Prev Close
$2.81
Open
$2.85
Day's High
$2.89
Day's Low
$2.85
Volume
349
Avg. Vol
8,310
52-wk High
$9.36
52-wk Low
$2.35

Search Stocks

Summary

Name Age Since Current Position

Peter Langecker

62 2011 Chairman of the Board, Chief Executive Officer

Barbara Riching

54 2013 Chief Financial Officer, Vice President

David Chaplin

57 2013 Director

Tamar Howson

64 2010 Independent Director

Gerald McMahon

58 2011 Independent Director

William Schwieterman

55 2007 Independent Director

Biographies

Name Description

Peter Langecker

Dr. Peter J. Langecker, M.D., Ph.D., is Chairman of the Board, Chief Executive Officer of Oxigene Inc. Dr. Langecker served as Chief Medical Officer of DURECT Corporation from May 2006 until June 2009. Prior to joining DURECT, Dr. Langecker served as Chief Medical Officer and Vice President of Clinical Affairs at Intarcia Therapeutics, Inc. from October 1999 to April 2006. Prior to that, Dr. Langecker was Vice President of Clinical Affairs at Sugen, Inc. from 1997 to 1999, Vice President, Clinical Research at Coulter Pharmaceuticals from 1995 to 1997 and Director of Clinical Research, Oncology, at Schering-Plough from 1992 to 1995. Previously, Dr. Langecker worked as a Project Physician-Central Medical Advisor, Oncology at Ciba-Geigy (now Novartis) in Basel, Switzerland. He received his M.D. degree and his doctorate in medical sciences from the Ludwig-Maximilians University in Munich.

Barbara Riching

Ms. Barbara Riching is Vice President and Chief Financial Officer of Oxigene Inc. She has many years of experience in the life sciences industry and is a certified public accountant. Ms. Riching joined the Company in December 2011 and from July 2012 until February 2013 served as the Company’s Interim Chief Financial Officer. She previously served as the Senior Director of Finance for Abgenix, Inc. from 1999 until 2005. Ms. Riching worked in finance positions at ALZA Corporation, Natural Wonders, Inc., and Ernst & Young LLP. She holds a Bachelor of Arts degree from the University of California at Santa Barbara.

David Chaplin

Dr. David Chaplin, Ph.D., is Director of Oxigene Inc. Since September 2011, Dr. Chaplin has been an independent consultant to biotechnology and pharmaceutical companies specializing in preclinical development. Dr. Chaplin served as Chief Scientific Officer and Head of Research and Development from July 2000 until August 2011. From 1999 to 2000, Dr. Chaplin served as Vice President of Oncology at Aventis Pharma in Paris. Prior to the merger of Rhone Poulenc Rorer (“RPR”) with Hoechst Marion Roussell, Dr. Chaplin was Senior Director of Oncology at RPR from 1998 to 1999. From 1992 to 1998, Dr. Chaplin headed up the Cancer Research Campaign’s (“CRC”) Tumor Microcirculation Group, based at the Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, London. During this time, he was also a member of the CRC Phase I/ II clinical trials committee. Dr. Chaplin also served as Section Head of Cancer Biology at Xenova in the U.K. from 1990 to 1992, and held a senior staff appointment at the British Columbia Cancer Research Centre from 1982 to 1990. Dr. Chaplin has a B.Sc. in chemistry from the University of Essex, a M.Sc. in pharmacology from the University of Southampton, and completed his Ph.D. in tumor biology at the University of London.

Tamar Howson

Ms. Tamar D. Howson is Independent Director of Oxigene Inc. Ms. Howson serves currently as a consultant to biotechnology companies and as a non-executive director to several life sciences companies. Ms. Howson was recently a Partner with JSB-Partners, a transaction advisory firm serving the life sciences industry. Formerly, she served as Senior Vice President of Corporate and Business Development and was a member of the executive committee at Bristol-Myers Squibb. During her tenure there, Ms. Howson was responsible for the company’s efforts in external alliances, licensing and acquisitions. Earlier, Ms. Howson served as Senior Vice President and Director of Business Development at SmithKline Beecham. She also managed SR One Ltd., the $100 million venture capital fund of SmithKline Beecham. Ms. Howson has served as an independent business consultant and adviser to companies both in the United States and in Europe. She held the position of Vice President, Venture Investments at Johnston Associates, a venture capital firm, and earlier as Director of Worldwide Business Development and Licensing for Squibb Corporation. Ms. Howson received her M.B.A. in finance and international business from Columbia University. Educated as a chemical engineer, she holds a M.S. from the City College of New York and a B.S. from the Technion in Israel.

Gerald McMahon

Dr. Gerald McMahon, Ph.D., is Independent Director of Oxigene Inc. Dr. McMahon currently serves as President and Chief Executive Officer of Kolltan Pharmaceuticals, Inc., based in New Haven, Connecticut. He has served in the positions of President and Chief Executive Officer of Kolltan since 2012. Previously, Dr. McMahon was Senior Vice President and Oncology Innovative Medicines Unit Leader of Medimmune LLC, a wholly owned subsidiary of Astra Zeneca PLC, a position which he held from 2010 through 2012. Dr. McMahon served as the Chief Executive Officer of Poniard Pharmaceuticals, Inc. from May 2004 to February 2010 and as the Chairman of the Board of Directors of Poniard from May 2004 to May 2011. He was a Venture Partner at Bay City Capital, LLC from February 2010 to October 2010. Dr. McMahon has spent more than 20 years as a business executive in the healthcare and biotech industries where he held various roles at Pfizer, Pharmacia, and Sandoz. In addition, Dr. McMahon was employed for 10 years at SUGEN. Dr. McMahon holds a B.S. in biology, earned a Ph.D. in 1980 in biochemistry from Rensselaer Polytechnic Institute and held post-graduate appointments at Tufts Medical School in Boston, Massachusetts and the Massachusetts Institute of Technology in Cambridge, Massachusetts.

William Schwieterman

Dr. William D. Schwieterman, M.D., is Independent Director of Oxigene Inc. Dr. Schwieterman has been the Chief Medical Officer of Chelsea Therapeutics, Inc., a publicly traded biopharmaceutical development company, since November 2009. He has been an independent consultant to biotech and pharmaceutical companies specializing in clinical development since July 2002. Dr. Schwieterman is a board-certified internist and a rheumatologist who was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA. In these capacities and others, Dr. Schwieterman spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a number of different types of molecules. Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati.

Basic Compensation

Name Fiscal Year Total

Peter Langecker

552,082

Barbara Riching

218,325

David Chaplin

721,641

Tamar Howson

--

Gerald McMahon

--

William Schwieterman

--
As Of 30 Dec 2012

Options Compensation

Search Stocks